Loading patent…
OwnerDaniel E. Afar, Rene S. Hubert +4inventors
InventorsDaniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Aya Jakobovits
Estimating the term…
Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells.
An isolated BPC-1 protein having the amino acid sequence as shown in FIG. 1, from amino acid residue number 1 through amino acid residue 158.
An isolated BPC-1 protein having the amino acid sequence as shown in FIG. 1, from amino acid residue number 24 through amino acid residue 158.
An isolated protein comprising at least one CUB domain of the BPC-1 protein as shown in FIG. 1, from about amino acid residue number 51 through about amino acid residue number 152.
An isolated polynucleotide comprising the precursor BPC-1 coding sequence as shown in FIG. 1 from nucleotide residue number 793 through 1269.
An isolated polynucleotide comprising the mature BPC-1 coding sequence as shown in FIG. 1 from nucleotide residue number 862 through 1269.
An isolated polynucleotide comprising the BPC-1 CUB domain coding sequence as shown in FIG. 1 from nucleotide residue number 943 through 1248.
A bi-specific monoclonal antibody which binds to two epitopes within the mature BPC-1 protein.
An assay for detecting the presence of a BPC-1 polynucleotide in a biological sample, comprising
An assay for detecting the presence of BPC-1 mRNA in a biological sample comprising:
A method of detecting the presence of a cancer expressing BPC-1 protein which comprises determining the level of BPC-1 protein expressed by cells in a test tissue sample from an individual, or in a serum, semen or urine sample from an individual, and comparing the level so determined to the level of BPC-1 expressed in a corresponding normal sample, the presence of elevated BPC-1 protein in the test sample relative to the normal sample providing an indication of the presence of such cancer in the individual.
A method of diagnosing the presence of cancer in an individual comprising:
A method of diagnosing the presence of cancer in an individual comprising:
A method of treating a patient with a cancer that expresses BPC-1 which comprises inhibiting the transcription of BPC-1 in the cells of said cancer.
A method of treating a patient with a cancer that expresses BPC-1 which comprises inhibiting the translation of BPC-1 mRNA in the cells of said cancer.
A method of treating a patient with a cancer that expresses BPC-1 which comprises inhibiting the processing of BPC-1 in the cells of said cancer.
A method of treating a patient with a cancer that expresses BPC-1 which comprises inhibiting the secretion of BPC-1 from the cells of said cancer.
A method of inhibiting the development of a cancer expressing BPC-1 in a patient, comprising administering to the patient an effective amount of the vaccine composition of claim 78 or 79.
Dependencies are inferred from the claim text.